Published through 2026-11-02 23:51 UTC · Automated cloud publishing.
Johnson & Johnson Reports Q3 2026 Results with Vision Care Growth and Raises Full-Year Guidance
Understand the event
Johnson & Johnson announced its financial results for the third quarter of 2026, highlighting a significant increase in worldwide sales. The company reported a 5.9 percent rise in total global revenue, reaching $25.4 billion. Within the MedTech segment, which includes vision care products, the company noted specific growth metrics. Vision care sales increased by 4.4 percent on a reported basis. Additionally, when adjusted for operational factors, this segment demonstrated a stronger performance with a 5.1 percent increase. These figures reflect positive momentum in the healthcare sector during the reporting period. Alongside the quarterly earnings release, Johnson & Johnson updated its outlook for the remainder of the fiscal year. The company raised its full-year guidance, indicating confidence in continued financial stability and growth potential across its various business units. This adjustment suggests that management expects to exceed previous projections based on current market conditions and internal performance trends.
AI-generated from reporting · updated 20 days ago
Reporting timeline
Follow the reporting for different perspectives.
- Vision Monday — BusinessJohnson & Johnson Reports Q3 2026 Results with Vision Care Growth and Raises Full-Year Guidance
Johnson & Johnson reported Q3 2026 financial results, showing a 5.9 percent increase in worldwide sales to $25.4 billion. Within the MedTech segment, vision care grew 4.4 percent on a reported basis and 5.1 percent operationally, primarily driven by strong contact lens sales, particularly the Acuvue Oasys 1-Day family. Surgical Vision also rose 7.1 percent, supported by demand for premium intraocular lenses like Tecnis PureSee and Tecnis Odyssey, which surpassed 1 million implants worldwide. The company received CE marking for Acuvue Oasys Max 2-Week reusable lenses in Europe. Consequently, J&J raised its full-year sales forecast to $101.0–$101.4 billion. Additionally, CFO Joe Wolk confirmed plans to separate the orthopedics business by mid-2027, while MedTech leadership acknowledged performance below internal standards.